At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Cilostazol 100Mg Tab +1 moredrug
Likely dose
Cilostazol 100Mg Tabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cilostazol for HFpEF (Heart Failure With a Preserved Ejection Fraction)
In Brief
A Phase 2 clinical trial evaluating Cilostazol 100Mg Tab and Placebo for Heart Failure With Preserved Ejection Fraction. Completed, enrolled 25 participants across 1 site.
Detailed Summary
Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without targeted evidence-based treatment. This will be assessed in a prospective 1-month single blinded study with 2 cross-overs n-of-1 study design with placebo and cilostazol
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedNov 2021
Primary CompletionJun 2022
Study CompletionJul 2022
TodayJul 2026
First PostedNov 19, 2021
Enrollment StartSep 1, 2021
Primary CompletionJun 1, 2022
Study CompletionJul 1, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.6 years ago
Interventions
Cilostazol 100Mg Tabdrug
Cilostazol Twice a Day
Placebodrug
Placebo